EP1023295A4 - Prodrogen von fibrinogenrezeptor-antagonisten - Google Patents

Prodrogen von fibrinogenrezeptor-antagonisten

Info

Publication number
EP1023295A4
EP1023295A4 EP98906092A EP98906092A EP1023295A4 EP 1023295 A4 EP1023295 A4 EP 1023295A4 EP 98906092 A EP98906092 A EP 98906092A EP 98906092 A EP98906092 A EP 98906092A EP 1023295 A4 EP1023295 A4 EP 1023295A4
Authority
EP
European Patent Office
Prior art keywords
fibrinogenic
predictions
receptor antagonist
antagonist
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98906092A
Other languages
English (en)
French (fr)
Other versions
EP1023295A1 (de
Inventor
Melissa S Egbertson
Steve D Young
George D Hartman
Jacquelynn J Cook
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9707489.2A external-priority patent/GB9707489D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP1023295A1 publication Critical patent/EP1023295A1/de
Publication of EP1023295A4 publication Critical patent/EP1023295A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP98906092A 1997-02-06 1998-02-02 Prodrogen von fibrinogenrezeptor-antagonisten Withdrawn EP1023295A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US3690197P 1997-02-06 1997-02-06
US36901P 1997-02-06
GBGB9707489.2A GB9707489D0 (en) 1997-04-14 1997-04-14 Fibrinogen receptor antagonist prodrugs
GB9707489 1997-04-14
PCT/US1998/001998 WO1998034935A1 (en) 1997-02-06 1998-02-02 Fibrinogen receptor antagonist prodrugs

Publications (2)

Publication Number Publication Date
EP1023295A1 EP1023295A1 (de) 2000-08-02
EP1023295A4 true EP1023295A4 (de) 2001-01-24

Family

ID=26311371

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98906092A Withdrawn EP1023295A4 (de) 1997-02-06 1998-02-02 Prodrogen von fibrinogenrezeptor-antagonisten

Country Status (5)

Country Link
EP (1) EP1023295A4 (de)
JP (1) JP2001512439A (de)
AU (1) AU747293B2 (de)
CA (1) CA2279927A1 (de)
WO (1) WO1998034935A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK171698A3 (en) 1996-06-14 1999-10-08 Biocryst Pharm Inc Substituted cyclopentane compounds useful as neuraminidase inhibitors
HUP0100142A3 (en) 1997-12-17 2002-01-28 Biocryst Pharmaceuticals Inc B Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors
US6025358A (en) * 1998-06-11 2000-02-15 G. D. Searle & Co. Double prodrugs of potent GP IIb/IIIa antagonists
AU1520300A (en) 1998-11-05 2000-05-29 Biocryst Pharmaceuticals, Inc. New cyclopentane and cyclopentene compounds and use for detecting influenza virus
EP1187825A1 (de) * 1999-06-07 2002-03-20 Shire Biochem Inc. Thiophen integrin inhibitoren
CN102015675B (zh) * 2008-02-21 2014-07-02 赛诺菲 作为凝血因子Xa和凝血酶的抑制剂的氯噻吩-酰胺
CN111943818B (zh) * 2020-09-16 2023-01-24 天津均凯农业科技有限公司 一种制备4,4′-双三氟甲基二苯醚的方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008577A1 (en) * 1992-10-14 1994-04-28 Merck & Co., Inc. Fibrinogen receptor antagonists
WO1994008962A1 (en) * 1992-10-14 1994-04-28 Merck & Co., Inc. Fibrinogen receptor antagonists
WO1994012181A1 (en) * 1992-12-01 1994-06-09 Merck & Co., Inc. Fibrinogen receptor antagonists
WO1994018981A1 (en) * 1993-02-22 1994-09-01 Merck & Co., Inc. Fibrinogen receptor antagonists
EP0656348A2 (de) * 1993-12-03 1995-06-07 F. Hoffmann-La Roche Ag Essigsäurederivate als Arzneimittel

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008577A1 (en) * 1992-10-14 1994-04-28 Merck & Co., Inc. Fibrinogen receptor antagonists
WO1994008962A1 (en) * 1992-10-14 1994-04-28 Merck & Co., Inc. Fibrinogen receptor antagonists
WO1994012181A1 (en) * 1992-12-01 1994-06-09 Merck & Co., Inc. Fibrinogen receptor antagonists
WO1994018981A1 (en) * 1993-02-22 1994-09-01 Merck & Co., Inc. Fibrinogen receptor antagonists
EP0656348A2 (de) * 1993-12-03 1995-06-07 F. Hoffmann-La Roche Ag Essigsäurederivate als Arzneimittel

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9834935A1 *

Also Published As

Publication number Publication date
WO1998034935A1 (en) 1998-08-13
CA2279927A1 (en) 1998-08-13
AU6141398A (en) 1998-08-26
EP1023295A1 (de) 2000-08-02
JP2001512439A (ja) 2001-08-21
AU747293B2 (en) 2002-05-16

Similar Documents

Publication Publication Date Title
NO20001100D0 (no) IL-8 reseptorantagonister
DE69812096D1 (de) Neuropeptid y rezeptorantagonisten
BR9712248A (pt) Antagonista receptores de vitronectina
NO986110D0 (no) IL-8 reseptor-antagonister
NO986109D0 (no) IL-8 reseptor-antagonister
DE69833073D1 (de) CCR-3-Rezeptor-Antagonisten
NO972016D0 (no) Indolyl-Y-reseptorantagonister
ATE280157T1 (de) 4-aroyl-piperidin-ccr-3 rezeptor antagonisten iii
NO993350D0 (no) Vitronectin-reseptor-antagonister
NO990668L (no) IL-8 reseptor antagonister
ID24726A (id) Antagonis-antagonis reseptor trombin
NO20001514D0 (no) Vitronectin-reseptor-antagonist
ID24162A (id) Antagonis-antagonis reseptor vitronektin
NO20001515D0 (no) Vitronektin reseptor-antagonist
DE69838874D1 (de) Il-8 rezeptor-antagonisten
MA25265A1 (fr) Antagoniste du recepteur de vitronectime.
ATE303370T1 (de) Il-8 rezeptor antagonisten
DE69824837D1 (de) Il-8-rezeptor-antagonisten
EP0912182A4 (de) Fibrinogen-rezeptorantagonistische prodrugs
EP0781133A4 (de) Fibrinogen-rezeptor-antagonisten
ID22978A (id) Antagonis reseptor endotelin
NO20010353L (no) IL-8 reseptor-antagonist
DE69830671D1 (de) Integrin-rezeptor-antagonisten
EP0812196A4 (de) Alpha 1a adrenergische rezeptorantagonisten
EP1185271A4 (de) Il-8 rezeptor antagonisten

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990906

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20001212

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 07D 487/00 A, 7C 07D 491/00 B, 7C 07D 495/00 B, 7C 07C 69/02 B, 7C 07D 487/04 B, 7C 07D 209/42 B, 7C 07D 333/38 B, 7C 07C 311/19 B, 7A 61K 31/55 B

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020301